Syreon Research Institute to collaborate on three new EU-funded clinical trials

Syreon will participate in three Horizon Europe-funded clinical trials, starting in summer 2023, coordinated by the European Organisation for Research and Treatment of Cancer (EORTC). The three projects will aim to optimise treatments for patients with refractory cancers through innovative clinical trials.

The three projects, DE-ESCALATE, LEGATO and STREXIT2, will span over five years, focusing on three different cancers - glioblastoma, prostate cancer and retroperitoneal sarcoma. The trials, involving hundreds of patients from over a dozen European countries, will form part of the European Cancer-mission. Organisations participating in the three projects include universities, hospitals, NGOs, as well as research laboratories and patient representative organisations.

As part of the projects, Syreon will conduct economic evaluations in different countries and will develop and coordinate a communication and dissemination strategy for the three projects. The results generated, if positive, should inform guideline developers, policymakers, and healthcare payers about the importance of giving access to investigational technologies for different types of cancers. Our team will also develop educational materials about key project methods and achievements.

To find out more about the three projects, visit: https://www.eortc.org/blog/2023/04/24/clinical-trials-funded-by-the-eu/